NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM
IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)
The clonoSEQ® Watch Registry
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM